Travere Therapeutics market cap is $1.9 b, and annual revenue was $198.32 m in FY 2020

Travere Therapeutics Gross profit (Q1, 2021)45.8 M

Travere Therapeutics Gross profit margin (Q1, 2021), %96.5%

Travere Therapeutics Net income (Q1, 2021)-53.9 M

Travere Therapeutics EBIT (Q1, 2021)-47.5 M

Travere Therapeutics Cash, 31-Mar-2021148.2 M

Travere Therapeutics EV1.9 B

USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 28.2m | 99.9m | 133.6m | 154.9m | 164.2m | 175.3m | 198.3m | ||

| 254% | 34% | |||||||

## Cost of goods sold | 571.0k | 2.2m | 4.6m | 3.6m | 5.5m | 5.2m | 6.1m | ||

## Gross profit | 27.6m | 97.7m | 129.0m | 151.3m | 158.7m | 170.1m | 192.2m | ||

| 98% | 98% | 97% | 98% | 97% | 97% | 97% | ||

## R&D expense | 524.0k | 7.1m | 47.8m | 50.4m | 70.9m | 78.2m | 123.8m | 141.0m | 131.8m |

## General and administrative expense | 1.3m | 17.7m | 59.6m | 79.5m | 92.8m | 101.3m | 103.7m | 129.0m | 135.8m |

## Operating expense total | 1.8m | 24.8m | 107.4m | 130.0m | 163.7m | 205.1m | 238.8m | 307.5m | 368.4m |

## EBIT | (24.0m) | (79.8m) | (50.7m) | (58.2m) | (53.8m) | (80.0m) | (137.4m) | (176.2m) | |

| (283%) | (51%) | (44%) | (35%) | (49%) | (78%) | (89%) | ||

## Interest expense | 105.9k | 46.3k | 7.4m | 7.7m | 759.0k | 1.2m | 5.5m | ||

## Interest income | 21.8k | 10.1m | 5.0m | ||||||

## Pre tax profit | (33.7m) | (113.4m) | 105.5m | (57.6m) | (58.4m) | (101.9m) | (146.4m) | (188.8m) | |

## Income tax expense | (1.9k) | (75.8k) | 2.5m | 11.8m | 9.7m | 1.4m | 811.0k | (21.0k) | (19.4m) |

## Net Income | (30.3m) | (33.8m) | (110.9m) | 117.2m | (47.9m) | (59.7m) | (102.7m) | (146.4m) | (169.4m) |

USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (30.3m) | (33.8m) | (110.9m) | 117.2m | (47.9m) | (59.7m) | (102.7m) | (146.4m) | (169.4m) |

## Depreciation and Amortization | 124.9k | 216.0k | 5.4m | 13.4m | 16.1m | 17.8m | 18.7m | 20.4m | 24.6m |

## Accounts Receivable | (8.0m) | (4.5m) | (6.1m) | 4.9m | 152.0k | (5.2m) | 2.3m | ||

## Inventories | (282.5k) | (1.2m) | (306.0k) | (1.7m) | (2.8m) | (2.0m) | (5.1m) | ||

## Accounts Payable | 680.9k | 2.8m | 20.3m | 3.4m | 9.7m | 2.7m | (2.7m) | 9.3m | (6.0m) |

## Cash From Operating Activities | (2.7m) | (17.6m) | (45.8m) | (554.0k) | (1.6m) | 7.4m | (25.0m) | (58.2m) | (42.7m) |

## Purchases of PP&E | 24.8k | (117.0k) | (662.6k) | (22.0k) | (1.4m) | (887.0k) | (727.0k) | (195.0k) | (6.8m) |

## Cash From Investing Activities | 1.7m | (5.4m) | (37.3m) | (80.6m) | 10.4m | 45.6m | (203.3m) | 19.9m | (61.3m) |

## Short-term Borrowings | (31.3m) | (45.0m) | |||||||

## Long-term Borrowings | (33.3k) | (500.2k) | (2.0m) | (1.0m) | (852.0k) | (41.2m) | |||

## Cash From Financing Activities | 4.4m | 29.0m | 95.3m | 100.8m | (5.7m) | 5.4m | 231.9m | (2.1m) | 127.7m |

## Net Change in Cash | 1.3k | 6.0m | 12.2m | 19.6m | 3.2m | 58.4m | 3.5m | (40.4m) | 22.3m |

## Interest Paid | 14.8k | 28.3k | 4.1m | 5.8m | 2.1m | 2.1m | 1.9m | 7.7m | 6.9m |

## Income Taxes Paid | 9.6m | 7.9m | 7.2m | 218.0k | 656.0k |

USD | Q2, 2012 |
---|